Liraglutide (NN2211) is a long-acting gluca on-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insuli secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxend as a treatment for obesity in adults with at least one weight-related comorbid condition.
| Product name | Liraglutide | |
| Appearance | white solid | |
| Purity | 99%min | |
| CAS No. | 204656-20-2 | |
| EINECS No. | 810-818-7 | |
| MF. | C172H265N43O51 | |
| Grade Standard | Medicine Grade | |
Application
Liraglutide is a once-daily injectable derivative of the human incretin glucagon-like peptide-1 (GLP-1), for the treatment of type
2 diabetes or obesity.
For high value products, please select air shipping and express delivery for safety.
Company Profile:
Shandong Longilat Biotechnology Co., Ltd was established in 2015. It is a high-tech professional and technological enterprise integrating R & D, production, and sales.
Longilat 's main products are food additives, plant extracts, cosmetic raw materials, feed additives, animal extract, amino acids and vitamins. Most of our products are derived from natural plants. Marketing services are available in many countries around the world.
